NASDAQ:XENE Xenon Pharmaceuticals Q4 2025 Earnings Results & Report $42.10 +0.71 (+1.72%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$41.88 -0.23 (-0.53%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Xenon Pharmaceuticals missed analyst earnings expectations in its Q4 2025 results, released February 26, 2026. The company reported EPS of -$1.31 versus the -$1.20 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 26, 2026TimeBefore Market OpensConference Call4:00 PM ET Xenon Pharmaceuticals EPS ResultsActual EPS-$1.31Consensus EPS -$1.20Beat/MissMissed by -$0.11One Year Ago EPS-$0.84EPS Beat Rate5 of last 8 quartersXenon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Xenon Pharmaceuticals Q4 2025 Earnings FAQ Did Xenon Pharmaceuticals beat earnings estimates for Q4 2025? Xenon Pharmaceuticals (NASDAQ:XENE) reported earnings of -$1.31 per share for Q4 2025, missing the consensus estimate of -$1.20. The report was announced on Thursday, February 26, 2026. Xenon Pharmaceuticals Earnings HeadlinesXenon Reports Q3 Results; Expects X-NOVA2 Data In December And Advances Pain Programs Toward Phase 2November 10 at 10:27 AM | rttnews.comXenon (XENE) Q3 2026 Earnings Call TranscriptNovember 10 at 10:27 AM | finance.yahoo.comTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.November 12 at 1:00 AM | USA Capital Gold (Ad)Xenon plans X-FIRST study in Q1 2027 as AZK NDA advances, with $1.2B cash into 2029November 9 at 12:08 AM | seekingalpha.comXenon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9 at 12:08 AM | marketscreener.comMIs Xenon Pharmaceuticals (XENE) Above Fair Value After Phase 2 Progress?November 9 at 12:08 AM | finance.yahoo.comSee More Xenon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenon Pharmaceuticals and other key companies, straight to your email. Email Address About Xenon PharmaceuticalsXenon Pharmaceuticals (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America. Its work includes discovering and developing therapies intended to address conditions with significant unmet medical needs.View Xenon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
